Investor Relations

NRx Pharmaceuticals is a clinical-stage, biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, is an oral, fixed dosed combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor.

The company has filed an Abbreviated New Drug Application (ANDA) for NRX-100, preservative-free IV ketamine and has initiated filing of an NDA for NRX-100 in people with suicidal depression.

NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is traded on the Nasdaq Global Select Exchange.